Elucidating the effect of crystallization on drug release from amorphous solid dispersions in soluble and insoluble carriers

被引:25
|
作者
Ojo, Andrew Toye [1 ]
Ma, Congshan [1 ]
Lee, Ping, I [1 ]
机构
[1] Univ Toronto, Leslie Dan Fac Pharm, Dept Pharmaceut Sci, Toronto, ON M5S 3M2, Canada
基金
加拿大自然科学与工程研究理事会;
关键词
Amorphous solid dispersion; Crystallization; Dissolution performance; Itraconazole; Polymorphs; Soluble and insoluble carriers; PHASE-SEPARATION; PHYSICAL STABILITY; IN-VITRO; IMPACT; DISSOLUTION; SOLUBILITY; SUPERSATURATION; CLASSIFICATION; ITRACONAZOLE; PERFORMANCE;
D O I
10.1016/j.ijpharm.2020.120005
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The development of amorphous solid dispersions (ASDs) is one way to overcome the bioavailability challenges of poorly water-soluble active pharmaceutical ingredients (APIs). An important consideration with ASD systems is that crystallization can occur during preparation, storage, and dissolution, thus reducing their bioavailability advantage. Currently, it is unclear whether the dissolution characteristics of the polymer carrier affects the dissolution performance of ASDs with intrinsic crystallization. Our aim was to differentiate the impact of a minor amount of intrinsic crystallinity (up to 10%) within soluble and insoluble carriers on ASD performance, using the area under the curve (AUC) values of non-sink dissolution profiles as a measure of dissolution performance that can inform in vivo bioavailability. In order to discern such differences, itraconazole (ITZ) ASDs were prepared by Hot Melt Extrusion (HME) with 50% (w/w) drug loading. PVP K12 and HPMCAS were used as the soluble and insoluble carriers in pH 1.2 dissolution media, respectively. Dissolution was also conducted in pH 6.8 buffer, wherein HPMCAS becomes soluble, to cross-validate experimental observations. Crystalline content was determined by differential scanning calorimetry (DSC) prior to dissolution. Soluble polymers differed from insoluble polymers in that crystals formed during processing and storage were released during dissolution which can undergo further growth causing a sharp decline in drug concentration in the dissolution medium. This led to a significant decrease in the AUC for soluble ASDs containing intrinsic crystallinity. In contrast, insoluble polymer carriers did not release the intrinsically formed crystals and the impact of subsequent crystal growth on dissolution performance was minimal for insoluble ASD systems. Furthermore, physical mixtures with spiked crystallinity were only found to reflect the dissolution performance of soluble ASDs exhibiting intrinsic crystallinity. Thus, in considering the impact of intrinsic crystallinity on ASD performance, the nature of the polymeric carrier in terms of solubility characteristics needs to be taken into account as there is significantly more variation in AUC with soluble carriers than insoluble carriers exhibiting intrinsic crystallinity.
引用
收藏
页数:9
相关论文
共 50 条
  • [21] Sustained-release amorphous solid dispersions
    Julien Maincent
    Robert O. Williams
    Drug Delivery and Translational Research, 2018, 8 : 1714 - 1725
  • [22] Effect of Polymer Molecular Weight on the Crystallization Behavior of Indomethacin Amorphous Solid Dispersions
    Mohapatra, Sarat
    Samanta, Subarna
    Kothari, Khushboo
    Mistry, Pinal
    Suryanarayanan, Raj
    CRYSTAL GROWTH & DESIGN, 2017, 17 (06) : 3142 - 3150
  • [23] Hydroxypropyl cellulose stabilizes amorphous solid dispersions of the poorly water soluble drug felodipine
    Sarode, Ashish L.
    Malekar, Swapnil A.
    Cote, Catherine
    Worthen, David R.
    CARBOHYDRATE POLYMERS, 2014, 112 : 512 - 519
  • [24] Microencapsulation of amorphous solid dispersions of fenretinide enhances drug solubility and release from PLGA in vitro and in vivo
    Nieto, Kari
    Mallery, Susan R.
    Schwendeman, Steven P.
    INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2020, 586
  • [25] Patterns of drug release as a function of drug loading from amorphous solid dispersions: A comparison of five different polymers.
    Saboo, Sugandha
    Moseson, Dana E.
    Kestur, Umesh S.
    Taylor, Lynne S.
    EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2020, 155
  • [26] Drug Release and Nanodroplet Formation from Amorphous Solid Dispersions: Insight into the Roles of Drug Physicochemical Properties and Polymer Selection
    Yang, Ruochen
    Mann, Amanda K. P.
    Tu Van Duong
    Ormes, James D.
    Okoh, Grace A.
    Hermans, Andre
    Taylor, Lynne S.
    MOLECULAR PHARMACEUTICS, 2021, 18 (05) : 2066 - 2081
  • [27] Effect of carrier type and Tween® 80 concentration on the release of silymarin from amorphous solid dispersions
    Mohylyuk, Valentyn
    Pauly, Thomas
    Dobrovolnyi, Oleksandr
    Scott, Nathan
    Jones, David S.
    Andrews, Gavin P.
    JOURNAL OF DRUG DELIVERY SCIENCE AND TECHNOLOGY, 2021, 63
  • [28] Delivery of Poorly Soluble Compounds by Amorphous Solid Dispersions
    Lee, Thomas W. Y.
    Boersen, Nathan A.
    Hui, H. W.
    Chow, S. F.
    Wan, K. Y.
    Chow, Albert H. L.
    CURRENT PHARMACEUTICAL DESIGN, 2014, 20 (03) : 303 - 324
  • [29] Injection moulded controlled release amorphous solid dispersions: Synchronized drug and polymer release for robust performance
    Deshmukh, Shivprasad
    Paradkar, Anant
    Abrahmsen-Alami, Susanna
    Govender, Rydvikha
    Viriden, Anna
    Winge, Fredrik
    Matic, Hanna
    Booth, Jonathan
    Kelly, Adrian
    INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2020, 575
  • [30] Solid Dispersions of Poorly Water Soluble Drug
    Gruberova, Lucie
    Kratochvil, Bohumil
    CHEMICKE LISTY, 2019, 113 (06): : 383 - 390